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1. Introduction
Community-acquired pneumonia (CAP) is a common and potentially serious illness [1]. It is
defined as an acute infection of the pulmonary parenchyma, occurring outside the hospital,
with clinical symptoms accompanied by the presence of pulmonary infiltrates on chest ra‐
diograph. With a prevalence estimated at nearly five million cases annually in United States,
emergency physicians and general practitioners diagnose and treat CAP on a regular basis
[2]; nearly one third of CAP patients arrived by emergency medical services, and half even‐
tually were admitted [3].
Community-acquired pneumonia is the major infection-related cause of death in developed
countries [4] and ranks as the third leading cause of all deaths in the world after ischaemic
heart disease and cerebrovascular disease [5]. Mortality from CAP ranges from less than 1%
in patients without risk factors treated as outpatients to 5-15% in hospital admitted patients
to greater than 20-30% in intensive care unit patients [6]. Pneumonia increases in frequency
with advancing age, and with associated comorbid medical illnesses (specially cardiovascu‐
lar, metabolic, neoplastic, respiratory and neurological disease) there is a significant increase
in morbidity and mortality [7].
Acute respiratory infections are a prevalent problem, affecting children, adults and the eld‐
erly, the main pathogens involved are respiratory viruses (rhinovirus, influenza, parainfluenza,
adenovirus, respiratory syncytial virus, metapneumovirus) and secondly bacteria (Streptococcus
pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Le‐
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gionella pneumophila, gram negative bacilli, and others), they are an important cause of
school and labor absenteeism, especially during the cold seasons [1,8].
The clinical manifestations associated with respiratory infections, such as malaise, fever,
chills, myalgia, sore throat, runny nose, cough, sputum production, chest pain and dyspnea,
can occur in different clinical contexts that differ in etiology, pathogenesis, clinical course,
treatment and prognosis [8,9]. Thus, the clinical picture may correspond to a mild self-limit‐
ed upper respiratory tract infection to a severe lung parenchyma infection that requires spe‐
cific treatment, as in cases of pneumonia and tuberculosis [10].
The reference standard to diagnose CAP is a new infiltrate on chest radiograph in the pres‐
ence of recently acquired respiratory signs and symptoms [11]. These include cough, in‐
creased sputum production, dyspnea, fever and abnormal auscultatory findings [12].
Unfortunately, clinical findings do not reliably predict radiologically confirmed pneumonia
[13]. Especially elderly people often present with atypical symptoms and without fever [14].
However physicians, especially in primary care, may not perform chest radiography and re‐
ly on the patient's history and physical examination [15].
The initial management of patients suspected of having community-acquired pneumonia is
challenging because of the broad range of clinical presentations, comprehensive differential
diagnosis, potential life-threatening nature of the illness, the need for antibiotic treatment
and associated high costs of care [16,17]. The initial testing strategies should accurately es‐
tablish a diagnosis and prognosis in order to determine the optimal treatment strategy, such
as decisions about the site of care (ambulatory or in-hospital), extension of microbiology and
laboratory assessments and antimicrobial recommendations.
The diagnosis is important to implement specific management measures, such as empirical
antibiotic treatment and prevention of complications, and the prognosis is important in de‐
termining the site of care (ambulatory, general ward or intensive care facilities) and define
treatment strategies to be implemented in each particular case [16,17]. This paper reviews
the sensitivity, specificity and accuracy of the history, physical examination, and laboratory
findings, individually and in combination, in diagnosing community-acquired pneumonia
and predicting short-term risk for complications and death from the infection.
2. Diagnosis of pneumonia
Primary-care physicians usually rely on patient history, and signs and symptoms to diag‐
nose or exclude pneumonia [10]. However, most signs and symptoms traditionally associat‐
ed with pneumonia (e.g. malaise, fever, cough, sputum production and dyspnea) are not
predictive of pneumonia in general practice [18]. Chest radiography (CXR) is the most fre‐
quently performed diagnostic investigation requested by general practitioners in the ambu‐
latory setting (primary care and emergency department) [19]. The history and physical
examination cannot provide a high level of certainty in the diagnosis of community-ac‐
quired pneumonia, but the absence of vital sign abnormalities and abnormal chest examina‐
tion findings substantially reduces the probability of the infection [20].
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The differential diagnosis of CAP includes several noninfectious causes, including pulmona‐
ry embolism, malignancy and congestive heart failure, among others [21]. The presence of a
non-infectious differential diagnosis is usually suspected only after failure of antibiotic ther‐
apy, with the ensuing risks related to untreated, potentially life threatening non-bacterial
disease [22]. Conversely, a delay of antibiotic treatment of more than 4-8 hours after hospital
admission is associated with increased mortality [23]. Hence, both a rapid diagnosis of CAP
and an accurate differentiation from viral respiratory illnesses and non-infectious causes has
important therapeutic and prognostic implications [24].
2.1. Medical history
In the initial diagnosis of the patient who complains of acute respiratory symptoms or fever
is necessary to establish the correct diagnosis based on clinical manifestations (history and
physical examination) and laboratory tests (e.g., blood cell count, chest radiograph, C-reac‐
tive protein, procalcitonin, etc.) that are available in ambulatory practice. This requires
knowledge of the epidemiology of respiratory infections in the geographic area, together
with the sensitivity and specificity of the clinical history and physical signs abnormalities in
diagnosing pneumonia [18].
The primary care physicians are often being confronted with patients presenting with non‐
specific constitutional symptoms (e.g., malaise, fever, chills, myalgia, headache, anorexia) or
respiratory symptoms (e.g., cough, sputum production, chest pain, dyspnea), and must to
establish a presumptive diagnosis based on their knowledge of the local epidemiology of
acute respiratory infections and the main findings on clinical history and physical examina‐
tion. Unfortunately clinical manifestations at presentation distinguish poorly between com‐
munity-acquired pneumonia and other causes of respiratory illnesses (view differential
diagnosis on Table 1). The likelihood ratio (LR) for these findings ranges between 1 and 3,
which is not useful to confirm the diagnosis of pneumonia (Table 2) [25-29]. In general, the
presence or absence of preexisting diseases, respiratory or constitutional symptoms does not
have a substantial effect on the probability of pneumonia.
Five studies based in emergency departments have assessed the characteristics of individual
items in the clinical history in the diagnosis of community-acquired pneumonia in adult pa‐
tients [25-29]. In each of these studies, the reference standard for the diagnosis of pneumonia
was a new infiltrate on a chest radiograph with or without clinical monitoring during one
month. Table 2 summarizes the likelihood ratios associated to main clinical findings ob‐
tained from the history, including general manifestations, preexisting diseases and respira‐
tory symptoms. Differences on results reflect, in part, variation in the selection criteria for
each study. For example, chest radiographs were obtained for all patients presenting with
acute cough in one study [25], while the other studies obtained chest radiographs only when
the emergency physician previously determined a need for them, often to confirm or ex‐
clude a suspected diagnosis of pneumonia [26-29]. The latter approach provides a more
highly selected population of patients with acute respiratory complaints that may change
the measured test characteristics of individual clinical findings. Thus, the prevalence of
pneumonia in study populations ranged from as low as 2.6% [25] to as high as 38.3% [26].
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There are no individual items from the clinical history whose presence or absence would re‐
duce or increase the odds of disease sufficiently to exclude or confirm the diagnosis of pneu‐
monia without obtain a chest radiograph [18,20]. Though the presence of fever,
comorbidities, history of dementia or immunosuppression may be helpful, they are not con‐
firmatory, particularly given the typically low prevalence of pneumonia in the primary
health services (2-5%) [1-3]. For example, when the estimated prevalence of pneumonia in
primary care services is around 2-3%, the presence of subjective fever (LR+=1.3-2.1) had a
positive predictive value (PPV) ranging between 2.6% and 6.2% [25,28,29], reflecting the low
prevalence of pneumonia in the ambulatory care setting. Meanwhile the presence of odyno‐
phagia or rhinorrhea (LR+=0.5-0.7) in the same context had a positive predictive value rang‐
ing between 1.0% and 2.1% [25,29].
Common causes
Upper respiratory tract infections
Acute bronchitis and bronchiolitis
Influenza - Flu















Cryptogenic organizing pneumonia (COP)
Table 1. Differential diagnosis of adult patients with community-acquired pneumonia in the primary health care
system.
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Variables Diehr et al Gennis et al Singal et al Heckerling et al Saldías et al
Cough ┄ NS 1.8 NS NS
Sputum
production 1.3 NS ━ NS 1.2
Dyspnea ━ 1.4 NS NS NS
Fever 2.1 NS ━ 1.7 1.3
Chills 1.6 1.3 ━ 1.7 1.4
Myalgias 1.3 NS ━ ━ NS
Odynophagia 0.7 NS ━ ━ 0.5
Rhinorrhea 0.7 NS ━ ━ 0.5
HR > 100/min NS 1.6 NS 2.3 1.4
RR > 20/min ━ 1.2 ━ ━ 1.3
T > 37.8 °C 4.4 1.4 2.4 2.4 2.2
Normal
vital signs ━ 0.2 ━ ━ 0.3
Dullness to
percussion NS 2.2 ━ 4.3 3.8
Ronchi NS 1.5 ━ 1.4 NS
Bronchophony ━ ━ ━ 3.5 9.5
Crackles 2.7 1.6 1.7 2.6 2.0
Normal lung
exam ━ 0.5 ━ ━ 0.4
LR+: positive likelihood ratio for pneumonia (sensitivity/1-specificity). HR: heart rate, RR: respiratory rate, T: tempera‐
ture. Normal vital signs: heart rate < 100 beats/min, respiratory rate < 20 breaths/min and temperature < 37.8 °C. NS:
result not significant.
Table 2. Predictive value of clinical manifestations (symptoms and signs) associated with the diagnosis of community-
acquired pneumonia in adults (LR+)[25-29].
2.2. Physical examination
The effect of vital sign abnormalities (e.g., tachycardia, tachypnea, fever) or pulmonary ex‐
am findings (e.g., decreased breath sound, bronchophony, dullness on percussion, rhon‐
chus, crackles) on the probability of pneumonia depends on the cut-off value to define an
abnormal result. For example, a respiratory rate greater than 20 breaths/min had a LR+ of 1.2
to 1.3 [26,29], whereas a respiratory rate greater than 25 breaths/min had a LR+ of 1.5 to 3.4
[25,28] (Table 2). When the estimated prevalence of pneumonia in primary care services is
around 2-3%, the presence of crackles on pulmonary examination (LR+=1.6-2.7) had a posi‐
tive predictive value ranging between 3.2% and 8.1% [25-29]. In contrast, two studies have
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shown that having a normal heart rate (below 100 beats/min) without fever (temperature <
37.8 °C) and tachypnea (respiratory rate < 20 breaths/min) reduces significantly the probabil‐
ity of community-acquired pneumonia (LR- = 0.18), thereby reducing the pretest odds of
pneumonia by more than fivefold [26,29].
In the Chilean study [29], the major clinical predictors of pneumonia were fever (≥38 °C),
tachypnea (≥20 breaths/min),  mental  confusion,  orthopnea,  cyanosis,  dullness on percus‐
sion, bronchophony, crackles and oxygen saturation less than 90% breathing room air (LR
+:  2.0  to 9.5).  In contrast,  sore throat,  runny nose,  normal vital  signs and lung ausculta‐
tion without clinical  abnormalities  were less frequent in patients with final  diagnosis  of
pneumonia (LR+: 0.3-0.5). Unlike other studies, Saldías et al. examined some combinations
of  symptoms and signs  showing that  significantly  increases  the  pretest  probability.  The
combination of clinical variables increase the probability of pneumonia, such as the pres‐
ence of fever and tachypnea associated with orthopnea, dullness on percussion, crackles
or  oxygen saturation below 90% (LR+:  4.9  to  14.7).  At  the same time,  the probability  of
pneumonia is very low in patients presenting with respiratory symptoms and normal vi‐
tal signs and lung auscultation (LR+: 0.1).
In summary, individual symptoms and signs at presentation distinguish poorly between
community-acquired pneumonia and other causes of respiratory illnesses [13,18,20]. Thus,
in 10-20% of ambulatory patients with a suspected lower respiratory tract infection CXR is
requested [19]. CXR can diagnose pneumonia in cases with the presence of pulmonary infil‐
trates and differentiate pneumonia from other conditions that may present with similar
symptoms (e.g., acute bronchitis or influenza) [2,3]. In addition, the results may suggest spe‐
cific aetiologies (e.g., lung abscess, TB infection), identify coexisting conditions (e.g., bron‐
chial obstruction, pleural effusion, neoplasms) and evaluate the severity of illness (e.g.,
multilobar or bilateral infiltrates, rapid progression of infiltrates, pleural effusion) [6,8]. Al‐
though chest radiography is frequently used for diagnosing pneumonia, little is known
about the influence of CXR on the probability estimation of pneumonia by general practi‐
tioners and on change in patient management [18,20]. Chest radiography is considered the
gold standard for pneumonia diagnosis; however, we do not know its sensitivity and specif‐
icity, and we have limited data on the clinical implications of false-positive and false-nega‐
tive results [18]. In the absence of empirical evidence, the decision to order a chest
radiograph needs to rely on expert opinion in seeking strategies to optimize the balance be‐
tween harms and benefits [16,17].
2.3. Clinical judgment and decision guidelines
Although physicians often planning the diagnostic and laboratory exams considering the
prevalence of the disease and its estimate of the probability in the population being evaluat‐
ed, the diagnostic threshold of professionals varies considerably even when faced with simi‐
lar clinical situations [30,31]. As the predictive value of individual signs and symptoms to
the diagnosis of pneumonia is relatively low, to resolve this problem, it has been designed
some predictive rules or decision guidelines incorporating the presence or absence of specif‐
ic clinical findings intended to guide clinicians in the management of patients with similar
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clinical features [18,20]. In the literature we find several protocols or decision rules that are
designed specifically to help primary care physicians in the assessment of adult patients
with lower respiratory tract infections (Table 3) [25-29,32-34]. Thus, in the clinical practice
guidelines is often recommended to primary care physicians request of chest radiography in
patients presenting respiratory symptoms based on some of these decision rules, in order to
optimize patient`s care [16,17,35].







RR > 25 breaths/min









Heckerling et al. Each variable scores a point.
Heart rate > 100 beats/min




Gennis et al. If one or more variables are present requesting chest radiograph.
Heart rate > 100 beats/min
Respiratory rate > 20 breaths/min
Temperature > 37.8 °C
Singal et al. Estimating the probability of pneumonia.
Probability = 1/(1 + e-Y)
Where Y: -3.095 + 1.214 x Cough + 1.007 x Fever + 0.823 x Crackles
Each variable = 1 if present
Melbye et al. A logistic regression model is proposed for the diagnosis of pneumonia.
Y= + 4.7 for fever (reported by patient) with duration of illness of one week or more; – 4.5 for coryza; – 2.1 for sore
throat; + 5.0 for dyspnea; + 8.2 for lateral chest pain; + 0.9 for crackles.
González Ortiz et al. A logistic regression model is proposed for the diagnosis of pneumonia.
Y= –1.87; + 1.3 for pathologic auscultation; + 1.64 for neutrophilia; + 1.70 for pleural pain; + 1.21 for dyspnea.
Hopstaken et al. A logistic regression model is proposed for the diagnosis of pneumonia.
Y= –4.15; + 0.91 for dry cough; + 1.01 for diarrhea; + 0.64 for temperature ≥ 38 °C; + 2.78 for C-reactive protein ≥ 20
mg/L.
Table 3. Clinical predictive rules for pneumonia diagnosed by chest radiography in the ambulatory care
setting[25-28,32-34].
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Prediction rules based on clinical information have been developed to support the diagnosis
of pneumonia and help limit the use of expensive diagnostic tests [36,37]. However, these
prediction rules need to be validated in the primary care setting. Several clinical prediction
rules have been developed to predict pneumonia in adults but they were not superior to
clinical judgment to predict pneumonia in the ambulatory setting [20,36,37]. In summary,
combination of history and physical examination findings at presentation only moderately
increase the probability of pneumonia. Thus, the clinical guidelines endorse the need for
chest radiography to confirm all diagnoses of community-acquired pneumonia [16,17,35].
In two predictive rules, described by Diehr et al. [25] and Heckerling et al. [28], the pretest
probability of pneumonia is amended according to the presence or absence of certain specif‐
ic symptoms. While other rule, described by Singal et al. [27], was designed using a logistic
regression analysis and provides a probability of pneumonia ranging from 4% (absence of
symptoms and signs) to 49% (presence of cough, fever and crackles). On the other hand,
Gennis et al. [26] suggested applying chest radiograph in patients with suspected of CAP
and alteration in any vital signs (heart rate above 100 beats/min, respiratory rate above 20
breaths/min or temperature higher than 37.8 °C). Melbye et al [32], González Ortiz et al. [33]
and Hospstaken et al. [34] proposed a logistic regression model for diagnosis of pneumonia
based on clinical and laboratory variables.
Two prospective studies have examined the predictive value of clinical judgment and four
clinical predictive rules in the diagnosis of community-acquired pneumonia in adults
[37,38]. Emerman et al. [37] compared physician judgment in the use of chest radiographs
for diagnosing pneumonia with decision rules developed by Diehr, Singal, Heckerling, and
Gennis in the emergency department and medical outpatient clinic of a major urban teach‐
ing hospital. The prevalence of pneumonia in this study was 7%, they found that clinical
judgment allowed to reduce the application of unnecessary chest radiographs better than
the four predictive rules (LR-= 0.25, 95%CI: 0.09 to 0.61) while clinical judgment allowed to
increase the likelihood of pneumonia to around 13% (LR+ = 2.0, 95%CI: 1.5 to 2.4), which
would have led to demand many unnecessary radiographic examinations. Among the four
examined predictive rules, the application of x-ray only to patients with abnormal vital
signs recommended by Gennis et al. [26] had higher diagnostic yield with a LR+ of 2.6
(95%CI: 1.6 to 3.7), which would have reduced by 40% the application of unnecessary radio‐
graphic examinations but would not have detected 38% of pneumonias confirmed by radiol‐
ogy (LR- = 0.50, 95%CI: 0.27 to 0.78 compared with LR- = 0.18 of the original study of Gennis
et al.) [34]. The sensitivity of physician judgment (86%) exceeded that of all four decision
rules (62-76%), but the higher specificity and accuracy of two of the decision rules [26,28]
suggested that they may have a role in patient evaluation.
Saldías et al. [29,38] have shown that clinical diagnosis of pneumonia made by physicians in
the emergency department had better sensitivity (range: 75-83%) than specificity (range:
47-83%) and better negative predictive value (NPV) (range: 85-91%) than PPV (range:
36-70%) (Table 4). In fact, a less experienced emergency physician had lower PPV and spe‐
cificity compared to internal medicine and respiratory disease physicians (Table 5). The
chance to change the initial diagnosis of pneumonia or positive likelihood ratio of three
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emergency physicians ranged between 1.5 and 4.8. Similar findings were described by Wipf
et al. [39], who determined the accuracy of various physical examination maneuvers in diag‐
nosing pneumonia and compared the interobserver reliability of the maneuvers among
three examiners. The authors concluded that the clinical findings investigated in chest ex‐
amination does not confirm or exclude with certainty the diagnosis of pneumonia, and the
degree of interobserver agreement was highly variable for different physical examination
findings.
Variables Clinical diagnosis Diehr et al Singal et al Heckerling et al Gennis et al
%, (95% CI) %, (95% CI) %, (95% CI) %, (95% CI) %, (95% CI)
Sensitivity 0.79 (0.72-0.84) 0.77 (0.70-0.83) 0.76 (0.69-0.82) 0.84 (0.78-0.90) 0.92 (0.87-0.96)
Specificity 0.66 (0.63-0.69) 0.64 (0.61-0.68) 0.54 (0.51-0.58) 0.41*(0.38-0.44) 0.31*(0.28-0.33)
PPV 0.55 (0.50-0.59) 0.54 (0.49-0.58) 0.46 (0.42-0.50) 0.43 (0.39-0,45) 0.42 (0.39-0.44)
NPV 0.85 (0.81-0.89) 0.84 (0.79-0.88) 0.81 (0.76-0.86) 0.84 (0.77-0.89) 0.88 (0.80-0.94)
Accuracy 0.70 (0.65-0.75) 0.69 (0.67-0.74) 0.62 (0.57-0.67) 0.56*(0.50-0.62) 0.53*(0.47-0.59)
LR+ 2.3 (1.9-2.7) 2.2 (1.8-2.6) 1.7 (1.4-1.9) 1.4* (1.2-1.6) 1.4* (1.2-1.4)
Note: 95% CI: confidence interval of 95%, PPV: positive predictive value; NPV: negative predictive value. * p <0.05
compared with clinical judgment.
Table 4. Predictive value of clinical judgment and four predictive rules in the diagnosis of community-acquired
pneumonia in adults[38].
Clinical diagnosis Sensitivity Specificity PPV NPV LR+
Physician A 83% 83% 70% 91% 4.8
Physician B 75% 73% 56% 86% 2.8
Physician C 77% 47% 36% 85% 1.5
Average 79% 66% 55% 85% 2.3
Note: Physicians A and B were specialists in internal medicine and respiratory disease over five years of professional
practice. Physician C was an emergency medicine specialist with less than three years of clinical practice.
Table 5. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and positive likelihood
ratio (LR+) for clinical diagnosis of community-acquired pneumonia[29].
Lieberman et al. [40] evaluated the reliability of physicians’ judgement relating to the pres‐
ence of pneumonia in adult patients with acute respiratory symptoms by clinical assessment
alone compared with chest X-ray. Physicians’ judgements of pneumonia had a sensitivity of
74% (95% CI 49-90%), a specificity of 84% (95% CI 78-88%), a NPV of 97% (95% CI 94-99%)
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and a PPV of only 27% (95% CI 16-42%). They concluded that the ability of physicians to
negate radiologically confirmed pneumonia by clinical assessment in febrile adult respirato‐
ry tract infection patients was good, but that their ability to successfully predict this condi‐
tion was poor.
In other study developed in two emergency departments from Madrid, Spain; Gonzalez et
al. [33] showed that the clinical judgment had low sensitivity for the diagnosis of pneumo‐
nia (45%) with a moderate PPV (80%). The sensitivity and specificity of clinical diagnosis of
pneumonia established by emergency medicine physicians were similar or slightly higher
compared with the four clinical predictive rules described in the literature [37,38]. The area
under the curve (AUC) of clinical judgment and the clinical decision rule described by Diehr
et al. for diagnosis of pneumonia were similar (AUC = 0.79 and 0.75, respectively), and both
were higher than those described by Heckerling (AUC = 0.70), Singal (AUC = 0.70) and Gen‐
nis et al. (AUC = 0.67) [38].
In summary, the clinical findings (history and physical examination) have only moderate
sensitivity and specificity for diagnosis of pneumonia in immunocompetent adult patients
presenting with fever or respiratory symptoms in the ambulatory care setting (Table 6).
None of the decision rules described in the literature have been superior to clinical judgment
in the diagnosis of pneumonia, yet no studies have examined its real contribution in the
evaluation and management of patients presenting with respiratory symptoms or fever in
the primary care services.
Clinical diagnosis Sensitivity Specificity PPV NPV LR+_
González et al. 45% 93% 80% 74% 6.6
Wipf et al. 47-69% 58-75% 48-64% 57-72% 1.1-2.0
Emerman et al. 86% 58% 14% 98% 2.0
Lieberman et al. 49-90% 78-88% 16-42% 94-99% ____
Saldías et al. 75-83% 47-83% 36-70% 85-91% 1.5-4.8
Note: PPV: positive predictive value, NPV: negative predictive value, LR: likelihood ratio.
Table 6. Predictive value of clinical judgment in diagnosing community-acquired pneumonia in adults[29,37,39-41].
2.4. Biomarkers and lower respiratory tract infection diagnosis
Numerous non-infectious processes can produce respiratory symptoms and new pulmonary
infiltrates with systemic inflammatory signs and symptoms that can be easily confused with
bacterial pneumonia (Table 1). Typically, Gram stains of respiratory secretions are often un‐
available or are difficult to evaluate, and microbiological culture reports take at least 24 to 48
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hours. A negative sputum or blood culture in a patient suspected of having community-ac‐
quired pneumonia does not rule out the possibility of a severe lower respiratory tract infec‐
tion [41]. Given these areas of uncertainty in clinical decision-making, a concerted effort has
been undertaken to develop reliable and practical biomarkers for the diagnosis, risk predic‐
tion and management of CAP. To be helpful in routine clinical practice, a biomarker should
provide additional actionable information – not already available by standard methods –
that accomplishes at least one or more of the following: a) Assists in establishing a rapid and
reliable diagnosis; b) Provides an indication of prognosis; c) Selects those patients most like‐
ly to benefit from a specific intervention; d) Reflects the efficacy or lack of efficacy of specific
interventions.
The usefulness of biomarkers for diagnosing lower respiratory tract infections (LRTI), and
identifying particular disease entities amongst LRTIs (e.g., acute bronchitis, influenza,
COPD exacerbation, pneumonia) is still a matter of controversy.
2.4.1. C- reactive protein
Some observational studies indicate that C-reactive protein (CRP) may have some role in
identifying patients with community-acquired pneumonia. Almirall et al. found significant‐
ly higher CRP values in adult patients with confirmed CAP compared to healthy controls
and suspected CAP [42]. Flanders et al. evaluated CRP as a possible tool in the differential
diagnosis of 168 adults with acute cough less than three weeks [43]. CRP levels correlated
with the presence of pneumonia but not with its severity. A serum CRP level over 40 mg/L
had a sensitivity of 70% and specificity of 90% to identify pneumonia. Holm et al. confirmed
the low sensitivity (73%) and specificity (65%) of serum CRP in the differential diagnosis of
LRTIs [44]. The authors concluded that only very high CRP levels (>100 mg/L) can be used
as indicator for the presence of CAP. Accordingly, Stolz et al. showed that the specificity of
CRP at the cut-off value of 100 mg/L to predict radiological confirmed pneumonia reaches
91.2% [45].
Falk et al. [46] assessed the diagnostic value of CRP in primary care and emergency depart‐
ments in terms of ruling in or ruling out CAP. Eight studies incorporating 2,194 patients
were included. The median prevalence of CAP was 14.6% (range 5%-89%). At a CRP cut-
point of less than 20 mg/L, the pooled positive LR+ was 2.1 (95%CI 1.8-2.4] and the pooled
negative LR– was 0.33 (95% CI 0.25-0.43). In conclusion, CRP may be of value in ruling out a
diagnosis of CAP in situations where pneumonia probability exceeds 10%, typically in emer‐
gency departments. However, in primary care services, additional diagnostic testing with
CRP is unlikely to alter the probability of CAP sufficiently to change subsequent manage‐
ment decisions such as antibiotic prescribing or referral to hospital.
2.4.2. Procalcitonin
Procalcitonin (PCT) is a 116 amino acid protein, precursor of calcitonin, which is physiologi‐
cally produced by the C-cells of the thyroid after intracellular processing of the prohormone.
The half-life of PCT is around 20-24 h and the plasma concentration in healthy individuals is
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typically below 0.1 μg/L. In some studies procalcitonin does not appear to be a significant
marker for CAP [47,48]. However, a more recent evaluation of the role of highly sensitive
CRP and PCT measurements showed a better discriminatory value of these biomarkers
compared to clinical signs [49]. The diagnostic accuracy of clinical signs and symptoms and
a range of laboratory markers were assessed in 545 patients with suspected lower respirato‐
ry tract infection admitted to the emergency department. The area under the curve of a clini‐
cal model including fever, cough, sputum production, abnormal chest auscultation and
dyspnea was 0.79 (95%CI, 0.75-0.83). Combining the values for procalcitonin and highly sen‐
sitive C-reactive protein together increased the AUC to 0.92 (95%CI, 0.89-0.94), which was
significantly better than the AUC for PCT, CRP and clinical signs and symptoms alone. The
contribution to diagnostic reliability made by PCT was substantially greater than that made
by CRP, which in turn performed better than the total leukocyte count. Clinical criteria such
as sputum production and physical examination with chest auscultation were poor predic‐
tors for the diagnosis of CAP. To predict bacteremia, PCT also had a higher AUC (0.85,
95%CI 0.80-0.91) as compared to CRP (0.71, 95%CI 0.62-0.80; p =0.01), leukocyte count (0.68,
95%CI 0.59-0.77; p = 0.002) and elevated body temperature (0.46, 95%CI 0.37-0.56; p < 0.001).
The added value of the PCT biomarker as a clinical decision-making tool has been evi‐
denced in several studies involving PCT measurement [50-57].
Circulating levels of the precursor hormone PCT, derived primarily from nonthyroidal tis‐
sues, can rise several thousand times above normal in various inflammatory conditions, but
most notably in bacterial infection [54]. In differentiating bacterial infection from non-infec‐
tive causes of inflammation in hospitalized patients, a meta-analysis concluded that PCT
was both more sensitive (85% vs. 78%) and more specific (83% vs. 60%) compared with CRP.
PCT was also more sensitive (92% vs. 86%) in differentiating between a bacterial etiology
and a viral etiology [55].
PCT and ventilator-associated pneumonia: The utility of PCT levels to improve the early diag‐
nosis of ventilator-associated pneumonia (VAP) has been evaluated in different studies. Due
to the use of dissimilar thresholds the results were not consistent [56-58]. Ramirez et al. re‐
port a cohort study with sequential measurement of PCT and CRP in well characterized pa‐
tients with VAP [59]. The results of this study showed that PCT and CRP plasma levels were
statistically higher in patients with confirmed VAP, PCT being the more accurate marker.
The combination of the simplified clinical pulmonary infection score (CPIS) and serum PCT
was able to exclude all false-positive diagnosis of VAP thus resulting in 100% specificity.
2.4.3. Soluble triggering receptor expressed by myeloid cell
The soluble triggering receptor expressed by myeloid cells-1 (sTREM) has been proposed as
another potentially useful diagnostic tool for CAP and VAP [58, 60-62]. The sTREM is upre‐
gulated by microbial products, it accurately identifies bacterial or fungal pneumonia in
bronchoalveolar lavage fluid (BAL) from mechanically ventilated patients, and is superior in
this regard to clinical findings or other laboratory values. Such intervention is not appropri‐
ate, however, in the routine care of patients with community-acquired pneumonia. In this
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setting, measurement of soluble triggering receptor expressed on myeloid cells-1 in plasma
or serum has proved unhelpful as a guide to either etiology or outcome [61].
The first study on 148 patients suffering from suspected CAP or VAP and receiving mechan‐
ical ventilation, sTREM was assessed in the BAL fluid and its levels were a better predictor
for bacterial infection than CPIS, TNF-alfa and IL-1 levels [58]. The authors also analyzed the
behavior of PCT and did not find any role for this biomarker in identifying pneumonia. An‐
other group evaluated the presence of sTREM in exhaled ventilator condensate (EVC) and in
BAL fluid from 23 patients clinically suspected of having VAP [60]. In contrast with the first
report, sTREM-1 was detected in the BAL fluid of all 14 VAP subjects but also in 8 of 9 sub‐
jects without pneumonia, and sTREM levels did not differ in the VAP subjects compared to
the non-pneumonia subjects. However, sTREM-1 was detected in the EVC from 11 of 14
subjects with VAP, but from only 1 of 9 subjects without VAP, and was significantly higher
in the pneumonia patients. Another study tends to rule out the value of sTREM detection in
BAL as a useful tool in VAP diagnosis [62]. In this study, 105 consecutive patients receiving
mechanical ventilation and undergoing BAL were enrolled. Of those, 19 patients (18.1%)
met definite microbiologic criteria for bacterial or fungal VAP. All the statistical analysis
performed showed that measurement of sTREM-1 was inferior to clinical parameters for the
diagnosis of VAP.
In patients with community-acquired pneumonia, traditional criteria of infection based on
clinical signs and symptoms, clinical scoring systems, and general inflammatory indicators
(for example, leukocytosis, fever, sputum and blood cultures) are often of limited clinical
value and remain an unreliable guide to diagnosis lower respiratory tract infections. Procal‐
citonin is superior to other commonly used markers in its specificity for bacterial infection,
allowing alternative diagnoses to be excluded, mainly as a guide to the necessity for antibi‐
otic therapy [63-65]. It can therefore be viewed as a diagnostic and prognostic test. It more
closely matches the criteria for usefulness than other candidate biomarkers such as C-reac‐
tive protein, which is rather a nonspecific marker of acute phase inflammation, and proin‐
flammatory cytokines such as plasma IL-6 levels that are highly variable, cumbersome to
measure, and lack specificity for systemic infection.
2.5. Pneumonia in elderly
The clinical presentation of pneumonia in the elderly may be subtle, lacking the typical
acute symptoms observed in younger adults. Riquelme et al. [66] reported the initial clinical
presentation of 101 elderly patients with CAP (mean age, 78 years; 66.3% men) who were
admitted to a 1000-bed teaching hospital in Barcelona, Spain. The most frequently observed
symptoms were dyspnea (72.3%), cough (66.3%), fever (63.4%), asthenia (57.4%), purulent
sputum (51.5%), anorexia (49.5%), altered mental status (44.6%), and pleuritic chest pain
(33.7%). The classic triad of symptoms of pneumonia − cough, dyspnea, and fever − was ob‐
served in only 30.7% of these elderly patients. Nineteen patients (18.8%) did not have cough,
purulent sputum, or pleuritic chest pain. In a prospective study [67] designed to assess the
clinical characteristics of 503 elderly patients (mean age, 76.3 years; 63.4% men) admitted for
CAP to 16 hospitals across Spain, the most frequently observed symptoms were cough
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(80.9%), fever (75.5%), dyspnea (69.8%), sputum production (65.8%), chills (53.1%), pleuritic
chest pain (43.3%), asthenia (38.6%), and altered mental status (25.8%). The typical constella‐
tion of symptoms of pneumonia (cough, purulent sputum, and pleural pain) was noted in
only 152 patients (30.2%). Metlay et al. [68] studied the influence of age on symptoms at pre‐
sentation in 1,812 patients with CAP. Cough, dyspnea, and pleuritic chest pain were signifi‐
cantly less common among elderly patients than among younger patients (81.7% vs. 87.8%,
68.8% vs. 73.9%, and 31.6% vs. 53.3%, respectively). After controlling for patient demo‐
graphics, comorbidities, and severity of illness, elderly patients exhibited significantly fewer
respiratory symptoms than did younger patients (respiratory symptom score, 7.21 vs. 9.79,
respectively; p < 0.01). In other study, altered mental status and the absence of fever were
observed more frequently in patients over 80 years of age than in those under 80 years of
age (21.0% vs. 10.7%; p < 0.001 and 32.1% vs. 21.9%; p < 0.001, respectively). These findings
are consistent with Saldías et al. study [69], which reported a higher incidence of dyspnea
and confusion (71% vs. 53%; p < 0.001 and 28% vs. 8%; p< 0.001, respectively) but a lower
incidence of fever, chills and pleuritic chest pain in the older patients (63% vs. 76%; p =
0.007, 21% vs. 41%; p < 0.001 and 12% vs. 32%; p< 0.001, respectively). Compared to adults
below 65 years of age hospitalized for CAP during the same period, the following clinical
findings were more prevalent among the elderly population: the presence of comorbidity,
dyspnea, decreased level of consciousness, suspected aspiration, hypoxemia and high serum
urea nitrogen on admission to hospital. In the elderly, admission to intermediate and inten‐
sive care units was more frequent (47.7% vs. 29.2%, p< 0.001), and the length of hospital stay
was longer (10.6 vs. 8.6 days, p= 0.03). Multilobar radiographic involvement, pleural effu‐
sion, the hospital complication rate and the need for mechanical ventilation were similar in
both groups, but mortality, both in-hospital and at 30-days follow-up, was higher in the eld‐
erly population (9.8% vs. 3.2%; p= 0.03 and 13.1% vs. 4.8%; p= 0.02, respectively). Further‐
more, it has been suggested that the local inflammatory response to infection of the lungs is
decreased in the elderly, resulting in less cough and sputum production [70]. The systemic
inflammatory response (e.g., fever, leukocytosis, high serum C-reactive protein) is also re‐
duced secondary to decreased production of cytokines. Nevertheless, the decrease in inter‐
leukin-6 (IL-6), the most prevalent mediator of fever, did not reach statistical significance in
a study that measured IL-6 levels in 59 elderly patients and 21 younger patients with CAP
(211.6 vs. 284.5 pg/mL, respectively) [71]. In contrast, tachypnea remains prevalent and ap‐
pears to be a sensitive indicator of lower respiratory tract infection in the elderly [69,72]. Al‐
tered mental status, confusion, a sudden decline in functional physical capacity, and
comorbidity decompensation may be the only symptoms of an infection (including pneumo‐
nia) in the elderly [66]. Clinicians should be cognizant of those symptoms to avoid delay in
establishing the diagnosis and initiating antibiotic therapy.
2.6. Recommendation
The clinical diagnosis of pneumonia without radiological confirmation lacks specificity be‐
cause the clinical feature (history and physical examination) does not allow differentiating
the patient with pneumonia from other acute respiratory diseases (e.g., upper respiratory
tract infections, bronchitis, bronchiolitis, influenza). The diagnosis of pneumonia based sole‐
Respiratory Disease and Infection - A New Insight112
ly on clinical criteria is also hampered by the large variability in the ability to detect focal
signs on chest examination between different examiners. Pneumonia remains foremost a
clinical diagnosis. However, symptoms of lower respiratory infection, including fever,
cough, purulent sputum, dyspnea, and pleuritic chest pain as well as the clinical findings of
fever, tachypnea, tachycardia, hypoxemia, and auscultatory signs of consolidation, are not
unique to pneumonia.
Although most patients with CAP can be managed successfully in the community by their
general practitioner without additional investigations, distinguishing CAP from other caus‐
es of respiratory symptoms and signs can be difficult, particularly where the presence of co‐
morbidities such as congestive heart failure, chronic lung disease, or COPD complicate the
clinical picture. The elderly can present a particularly difficult diagnostic challenge because
they more frequently present with non-specific or atypical symptoms and signs. Chest ra‐
diographs are therefore routinely required to confirm the clinical suspicion of pneumonia:
The clinical history and physical examination suggest the presence of a lower respiratory
tract infection, but the diagnosis is established when demonstrating the presence of new on‐
set pulmonary infiltrates on chest radiography.
3. Prognosis of pneumonia
3.1. Severity assessment in adult patients with community acquired pneumonia
Once community-acquired pneumonia is diagnosed, a combination of history, physical ex‐
amination, and laboratory exams can help estimate the short-term risk for torpid evolution
or death and, along with the patient’s psychosocial characteristics, determine the appropri‐
ate site of treatment [6,16,17,32]. These decisions, including the need for parenteral therapy
and supportive care, ultimately relate to the decision on whether to hospitalize the patient.
The wide spectrum of severity in patients presenting in the ambulatory care setting explains
the wide variation in case fatality rates for pneumonia reported in the national and interna‐
tional literature in different clinical contexts [1,4,6,8]. Thus adult patients with pneumonia
without risk factors treated in the ambulatory setting has a low mortality risk (1-2%), rising
to 5-15% in patients with comorbidities or specific risk factors that are admitted to hospital
ward and increases to 20-50% in those admitted to the intensive care unit. The severity as‐
sessment allow us to decide the site of care (outpatient or in-hospital: general ward, inter‐
mediate care unit or ICU), the extension of laboratory and microbiological examination,
coverage of empiric antibiotic treatment, route and length of treatment and level of medical
and nursing care that requires the particular case. Recognition of patients at low risk of com‐
plications that can be managed as outpatients would significantly reduce the costs of health
care, minimizing risks, without compromising the evolution and prognosis of CAP patients
[73]. Hospital admission rates of adult patients with community-acquired pneumonia re‐
ported in the literature vary considerably, suggesting that physicians do not use uniform cri‐
teria to assess the risk of morbidity and mortality of patients. It has been reported that
primary care physicians often overestimate the risk of complications and death in patients
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with CAP, hospitalizing consequently a significant number of patients at low risk [74]. The
risk stratification of patients should help to reduce this variability and improve the decision
of admission and cost effective management of the disease.
3.2. Clinical, radiographic and laboratory prognostic factors in community-acquired
pneumonia
Numerous studies have examined hospital or ICU admission risk factors associated with
complicated clinical course or poor prognosis in CAP patients, particularly related to hospi‐
tal or short-term mortality [6,16,17,69]. Univariate studies have described more than 40 clini‐
cal and laboratory parameters associated with mortality [6,36,69,75-77]. However, an
independent association with short-term risk of death or hospital complication rate was
found only for some clinical variables using multivariate analysis.
To facilitate handling of short-term prognostic factors in pneumonia, it is convenient to
group them in different categories: a) Sociodemographic factors: age, gender, origin, ethnici‐
ty, social factors; b) Clinical history: preexisting disease, immunosuppression, altered men‐
tal status, fever, cough, sputum production, dyspnea, chills, chest pain; c) Physical
examination: tachycardia, hypotension, tachypnea, hypothermia, hyperthermia, confusion,
or pulmonary exam abnormalities; d) Chest radiograph: multilobar or bilateral pulmonary
infiltrates, cavitation or pleural effusion; e) Laboratory tests: hypoxemia, hypercapnia,
acidosis, high blood urea nitrogen, anemia, leukopenia, leukocytosis, hypoalbuminemia, hy‐
perglycemia, and raised biomarkers of inflammation; f) Microbiological exams: bacteremic
pneumonia, lung infection by pneumococcus, anaerobic, atypical microorganisms, gram-
negative bacilli or S. aureus [6].
Age: Several studies have demonstrated an association between extreme ages (below one
year and over 65 years) and the risk of death in the hospital [4-6,14,23,78,79,82,83]. The com‐
munity-acquired pneumonia in the elderly usually manifests with atypical or nonspecific
symptoms (e.g., mental confusion, anorexia, arrhythmias, congestive heart failure), difficult‐
ing the diagnostic process and delaying specific treatment adversely compromising the
prognosis of patients [14,66,69,70]. The absence of fever, prostration, multiple comorbidities,
nutritional disorders and institutionalization are poor prognostic factors in the elderly
[14,66,72]. However, based on evidence from clinical studies, there are not reasons that sup‐
port the use of different clinical variables to assess the severity in elderly people.
Comorbidity: The presence of coronary heart disease, congestive heart failure, cerebrovascu‐
lar disease with motor dysfunction or dementia, diabetes mellitus, chronic respiratory dis‐
ease (COPD, bronchiectasis), cancer, immunosuppression, chronic renal failure, alcoholism,
malnutrition and chronic hepatic disease are associated to increased hospital mortality in
adult patients with pneumonia [6,69,75-77,83,85]. However, the contribution of different co‐
morbidities to severity of community-acquired pneumonia in adults has been difficult to es‐
tablish, due to lack of uniformity in the definition of chronic diseases in different studies
and stratification problems with the severity of various comorbidities. This could partly ex‐
plain the low predictive power of specific comorbidities as risk factors of death in multivari‐
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ate analysis, despite that large number of studies have shown its importance in the
univariate analysis.
Respiratory rate: Regardless of age of the patient, the presence of tachypnea is one of the most
reliable indicators of severity of pneumonia in univariate and multivariate analysis
[6,69,75-77,79,81-83,86,87]. There is a linear relationship between respiratory rate and mor‐
tality in pneumonia patients, but in the clinical practice, it is recommended that the respira‐
tory rate above of 20 breaths/min should be considered a reliable sign of severity in patients
with pneumonia.
Mental status: Altered mental status has been identified as an independent risk factor of
death in several studies, including elderly population [6,14,66,69,72,79,82]. However, the
definition of altered mental status has varied in different studies, thus complicating their in‐
tegration as a prognostic factor. Despite this, the quantitative or qualitative impairment of
consciousness are an excellent predictor of prognosis in patients with community-acquired
pneumonia.
Blood pressure: Systolic hypotension (SBP <90 mmHg) or low diastolic blood pressure (DBP ≤
60 mmHg) and the presence of septic shock on admission to hospital are independent fac‐
tors of poor prognosis in multivariate analysis of several studies [6,69,75-82,84]. In the ICU,
the presence of septic shock or prolonged systolic hypotension for more than 12 hours
which does not improve with adequate volume replacement and/or vasopressor drugs pre‐
scription is another sign of poor prognosis.
Oxygenation: Hypoxemia and oxygen administration with a FiO2 ≥ 0.5 to maintain adequate
tissue oxygenation or the application of PEEP are indicators of poor prognosis [6,78,79,83].
The severe acute respiratory failure and the need for mechanical ventilation in ICU admis‐
sion or during hospital stay are also predictors of mortality. The presence of hypoxemia or
hypercapnia should be corrected immediately and is a determining factor in deciding hospi‐
talization of a particular case.
Chest radiography: Bilateral or multilobar pulmonary opacities, rapid progression of pulmo‐
nary infiltrates over 72 hours, the presence of cavitation or pleural effusion are poor prog‐
nostic factors associated to hospital complications and short-term mortality [6,74-77,82-84].
The performance of serial chest radiographs to assess the clinical evolution of hospitalized
patients with pneumonia is not recommended outside the ICU, unless there is clinical evi‐
dence suggestive of treatment failure or a complication.
Leukocytes count: The presence of leukopenia (less than 4,000 leukocytes per mm3) or leuko‐
cytosis (greater than 20,000 leukocytes per mm3) on admission to hospital was associated
with high mortality in univariate analysis. However, multivariate analysis results have been
controversial and suggest that leukopenia may be a better predictor of mortality [6,79].
Renal function: The high blood urea nitrogen on admission to hospital has been recognized
as a poor prognostic factor in patients with community acquired pneumonia in the univari‐
ate and multivariate analysis, probably reflecting the deterioration of tissue perfusion
[6,69,75-77, 79,81,82]. It is important to emphasize, the main prognostic laboratory tests
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measured at admission in hospitalized adult patients with community-acquired pneumonia
are the arterial blood gases and measurement of uremia.
Microbiology:  Bacteremic pneumonia with positive blood cultures has two to three times
greater risk of death [6,75-77,83]. Pneumonia caused by gram negative bacilli, Staphylococ‐
cus aureus and Pseudomonas aeruginosa tend to have more complications during the evolu‐
tion  and  increased  lethality  [6,83].  Pulmonary  infection  by  Legionella  spp  is  a  common
cause of severe pneumonia and admission to the intensive care unit, specially reported in
Europe. However, the clinical-radiographic features has failed to differentiate between the
different etiologic agents of pneumonia; in this way, the late microbiological information
has not  been useful  for  assessing the severity of  the individual  patient  on admission to
hospital or in the context of attention in primary health care services (outpatient clinics or
emergency departments). Nevertheless, microbiological tests are useful for evaluating the
severity  and  guide  antimicrobial  therapy  in  patients  hospitalized  with  community-ac‐
quired pneumonia.
3.3. Clinical predictive rules to assess the severity of the patient with pneumonia
The evaluation of the severity of the patient with pneumonia depends on the experience of
the clinician, who has been reported often underestimate the seriousness of the disease [78].
No prognostic factor is sufficiently sensitive and specific for predicting the evolution of the
individual patient. Thus, in the medical literature have been described several prognostic in‐
dices that would help the clinician to identify patients with community acquired pneumonia
that have low or high risk of complications and/or death during the evolution (Table 7)
[76,79-82]. None of the developed predictive models has allowed stratifying patients into
well-defined risk categories. The development and dissemination of clinical guidelines that
examine the severity of the patient with pneumonia by objective criteria, have reduced the
hospitalization of low risk patients, significantly reducing the cost of medical resources
without affecting the evolution and prognosis of patients [16,17,35,88,89]. Severity predic‐
tive models based on clinical and laboratory exams are best viewed as adjunctive tools for
the clinical evaluation of patients. In general, predictive models should be used with care
and should never override clinical judgment. The periodic assessment of severity during the
course of hospital stay is mandatory to allow adjustment of empirical antibiotic treatment to
avoid adverse events associated to it.
Significant variation in admission rates among hospitals and among individual physicians
has been well documented. Physicians often overestimate severity and hospitalize a signif‐
icant number of patients at low risk for death [90,91]. Because of these issues, interest in
developing  simple  and  objective  clinical  criterias  available  at  primary  health  care  has
stimulated to develop such predictive rules by several research groups [76,79-82]. The rel‐
ative  merits  and  limitations  of  various  proposed  criteria  have  been  carefully  evaluated
[92]. The two most interesting predictive rules are the Pneumonia Severity Index (PSI) de‐
scribed by Fine et  al.  [81]  for  screening of  patients at  low risk for outpatient  treatment,
and the British Thoracic Society criteria (CURB-65) for screening of high risk patients with
severe CAP [79,80].
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Congestive heart failure 10
Cerebrovascular disease 10
Renal disease 10
Initial physical examination findings
Altered mental status 20
Respiratory rate ≥30 breaths/min 20
Systolic blood pressure < 90 mmHg 20
Temperature < 35 °C or ≥40 °C 15
Heart rate ≥125 beats/min 10
Initial laboratory findings
pH < 7.35 30
BUN > 30 mg/dL 20
Sodium < 130 mEq/L 20
Glucose ≥250 mg/dL 10
Hematocrit < 30% l10
PaO2 < 60 mmHg or O2 sat < 90% 10
Pleural effusion 10
Risk class Score Mortality Site of care recommendation
I 50 0.1 – 0.4% Outpatient
II 51 – 70 0.6 – 0.7% Outpatient
III 71 – 90 0.9 – 2.8% Short stay inpatient
IV 91 – 130 8.2 – 12.5 Inpatient
V > 130 27.1 – 31.1% Inpatient
British Thoracic Society criteria (CURB-65)
Confusion
BUN > 7 mmol/L or 20 mg/dL
Systolic BP < 90 mmHg or Diastolic BP ≤60 mmHg
Respiratory rate ≥30 breaths/min
Age ≥65 years
Risk categories Score Mortality Site of care recommendation
I 0 – 1 1.5% Outpatient
II 2 9.2% Inpatient
III 3 22% Inpatient (ICU admission)
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Severe Community Acquired Pneumonia score (SCAP)
Variables Score
Age ≥80 years 5
Systolic blood pressure < 90 mmHg 11
Respiratory rate > 30 breaths/min 9
Confusion 5
Blood urea nitrogen > 30 mg/dL 5
Multilobar or bilateral pulmonary infiltrates 5
PaO2 < 54 mmHg or PaO2/FiO2 < 250 6
pH < 7.30 13
Risk categories Score Severe CAP *
Low 0 – 9 0.19 - 3.4%
Intermediate 10 – 19 9.2 - 11.2%
High 20 36.6 - 75.8%
* Severe CAP was defined by hospital mortality, mechanical ventilation use and/or septic shock.
Table 7. Prognostic rules in adults patients with community-acquired pneumonia[79-81].
3.3.1. Pneumonia severity index
The PSI is  based on derivation and validation cohorts of  14,199 and 38,039 hospitalized
patients  with  CAP,  respectively,  plus  an  additional  2,287  combined inpatients  and out‐
patients [81]. The Pneumonia Severity Index allows us stratify patients into five risk cat‐
egories.  Patients  with  pneumonia  risk  class  I  have  low  risk  of  death  and  adverse
events, with a mortality rate ranging between 0.1% and 0.4%. In an observational study,
low-risk  patients  susceptible  to  ambulatory  care  had  a  30-days  hospitalization  rate
around  5.5%  [93].  The  model  described  by  Fine  et  al.  was  developed  as  a  two-stage
predictive tool  to identify low risk patients for ambulatory management.  In a first  step,
we  consider  some epidemiological  variables  (age,  gender,  nursing  home residence),  the
presence  of  certain  specific  comorbidities  (congestive  heart  failure,  malignancy,  chronic
liver disease, cerebrovascular disease and chronic kidney disease) and some physical ex‐
amination  abnormalities  (mental  status,  heart  rate,  blood  pressure,  respiratory  rate  and
temperature).  In  a  second step,  we consider  some laboratory  and radiographic  findings
(for  example,  anemia,  hypoxemia,  azotemia,  hyperglycemia  and  pleural  effusion).  On
the basis  of  associated mortality rates,  it  has been suggested that  risk class I  and II  pa‐
tients should be treated as outpatients, risk class III patients should be treated in an ob‐
servation  unit  or  with  a  short  hospitalization,  and  risk  class  IV  and  V  patients  should
be treated as inpatients (Table 7). In general, patients younger than 60 years without co‐
morbidities  and  abnormalities  in  mental  status  and  vital  signs  are  classified  into  low
risk categories,  which could be treated as outpatients unless there are social factors that
hinder  their  control  or  adherence to  treatment  (e.g.,  alcoholism,  drug addiction,  psychi‐
atric disorders or, rural origin).
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3.3.2. British thoracic society rule
To identify high-risk patients has been useful the discriminant rule developed by the British
Thoracic Society, confirming that advanced age, altered mental status or confusion, respira‐
tory rate above 30 breaths/min, diastolic blood pressure below 60 mmHg and blood urea ni‐
trogen greater than 20 mg/dL are associated with increased mortality [79,80]. The BTS
original criteria of 1987 have subsequently been modified [78-80]. In the initial study, risk of
death was increased 21-fold if a patient, at the time of admission, had at least 2 of the follow‐
ing 3 conditions: tachypnea, diastolic hypotension, and an elevated blood urea nitrogen lev‐
el. These criteria appear to function well except among patients with chronic renal failure
and among elderly patients [94,95]. The most recent modification of the BTS criteria includes
five easily measurable factors [80]. Multivariate analysis of 1,068 patients identified the fol‐
lowing factors as indicators of increased mortality: confusion (based on a specific mental test
or disorientation to person, place, or time), BUN level above 17 mmol/L (20 mg/dL), respira‐
tory rate over 30 breaths/min, low blood pressure (systolic, below 90 mm Hg; or diastolic,
below 60 mmHg), and age over 65 years; this gave rise to the acronym CURB-65. In the deri‐
vation and validation cohorts, the 30-day mortality among patients with 0, 1, or 2 factors
was 0.7%, 2.1%, and 9.2%, respectively. Mortality was higher when 3, 4, or 5 factors were
present and was reported as 14.5%, 40%, and 57%, respectively. The authors suggested that
patients with a CURB-65 score of 0-1 be treated as outpatients, that those with a score of 2 be
admitted to the wards, and that patients with a score of ≥ 3 often required ICU care. A sim‐
plified version (CRB-65), which does not require testing for BUN level, may be appropriate
for decision making in the primary care practitioner’s office [96].
3.3.3. Severe CAP rule
Severe CAP (SCAP) is a life-threatening condition that requires intensive care. Estimates of
the frequency of severe CAP range from 5 to 35%, with mortality ranging from 20 to 50% [6].
These relatively wide ranges indicate disparities between definitions of SCAP. There is no
universally accepted definition of SCAP. During the last decade, the term has been used for
cases that ultimately result in death, and/or patients requiring admission to an intensive care
unit. Such practical definitions seem to be insufficient because the risk of death from CAP is
not the same as the need for inpatient care. On the other hand, the decision to admit a pa‐
tient to the ICU depends on the clinical judgment of individual clinicians and the local prac‐
tices of their hospitals, differences that could account for much of the variability regarding
ICU admission. Studies focused on the evaluation of patients admitted to the ICU mix some
variables evident at the time of admission with other potentially evolutionary criteria, which
are not applicable to early hospital admission. Other criteria, such as mechanical ventilation
and septic shock, are less subject to interpretive variability and better reflect illness severity
[97]. España et al. [82] developed a clinical prediction rule for severe community-acquired
pneumonia (SCAP) in 1,057 adult patients visiting the emergency department from one hos‐
pital, which was then validated in two different populations: 719 patients from the same
center and 1,121 patients from four other hospitals. In the multivariate analyses, eight inde‐
pendent predictive factors were correlated with severe community-acquired pneumonia: ar‐
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terial pH below 7.30, systolic blood pressure under 90 mmHg, respiratory rate above 30
breaths/min, altered mental status, blood urea nitrogen over 30 mg/dL, oxygen arterial pres‐
sure under 54 mmHg or ratio of arterial oxygen tension to fraction of inspired oxygen under
250 mmHg, age greater than or equal to 80 years, and multilobar or bilateral lung affecta‐
tion. The SCAP score was designed to identify high risk patients at admission, by predicting
the hospital mortality, need for mechanical ventilation, and risk for septic shock.
The Severe Community Acquired Pneumonia score described by España et al. was validated
to predict 30-day mortality in an internal validation cohort of consecutive adult patients ad‐
mitted to one hospital [98]. Consecutive inpatients from other three hospitals were used to
externally validate the score and compare the SCAP with the PSI and CURB-65. The dis‐
criminatory power of these rules to predict 30-day mortality was tested by the area under
curve (AUC), and their predictive accuracy with the sensitivity, specificity and predictive
values. The 30-day mortality rate increased directly with increasing SCAP score (class 0:
0.5%, to class 4: 66.5% risk) in the internal validation cohort, and from 1.3% to 29.2% in ex‐
ternal cohort (p <0.001) with an AUC of 0.83 and 0.75, respectively (p= 0.024). The SCAP
score identified 62.4% (95%CI 58.8-66.0) low-risk patients, 52.5% (95%CI 48.8-56.2) the PSI
and 46.2% (95%CI 42.5-49.9) the CURB-65 in the external cohort. Patients classified as low
risk by the three rules had similar 30-day mortality (SCAP: 2.5%, PSI: 1.6% and CURB-65:
2.7%). The SCAP score was valid to predict 30-day mortality among low-risk patients and to
identify patients at low-risk was similar or greater than the other studied rules.
3.3.4. Generic sepsis scores
Generic scoring systems such as the systemic inflammatory response syndrome (SIRS) crite‐
ria and standardized early warning score (SEWS) have been extensively assessed in critical‐
ly ill patients and are relatively simple to calculate [99,100]. However, it has been reported
that SIRS and SEWS perform less favourably than CURB-65 and PSI scores for severity as‐
sessment in CAP and prediction of progression to sepsis in severe CAP [101,102]. Consider‐
ing the limited number of studies to date does not support use of generic sepsis scores over
pneumonia-specific scores in CAP.
The clinical pulmonary infection score (CPIS) - original or modified - has been proposed for
the diagnosis and management of ventilator-associated pneumonia [103, 104]. The clinical
pulmonary infection score has low diagnostic accuracy; however, incorporating gram stains
results into the score may help clinical decision making in patients with clinically suspected
pneumonia [105].
The use of APACHE II predictive model in the evaluation of patients with severe pneumonia in
the ICU has demonstrated its usefulness as a predictor of mortality [106,107]. However, it has
not been proved applicable in units of lower complexity of the hospital. The application of this
prognostic tool out of the ICU is difficult, time consuming and impractical.
3.3.5. Clinically relevant adverse outcome prediction
Severity scores provide pivotal direction for the management of community-acquired pneu‐
monia, helping guide decisions such as the appropriate venue for care, diagnostic strategies,
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and antibiotic therapies. The most popular severity scores, the pneumonia severity index
and CURB-65 are accurate for predicting pneumonia-related mortality [108-114]. But clinical
care should be based on a broader set of medical outcomes than just mortality, such as ICU
admission, need for mechanical ventilation, progression to severe sepsis, or treatment fail‐
ure [115,116]. Unfortunately, there is no consensus surrounding serious complications that
warrant hospitalization for patients with pneumonia.
It has been reported that the SCAP score is slightly better than the PSI and CURB-65 in predict‐
ing adverse outcomes other than mortality in two independent cohorts [117]. In the external
validation cohort, the rate of adverse outcomes increased steadily from low- to high-risk
classes for the SCAP score as well as for the PSI and CURB-65 (p < 0.001). In the internal valida‐
tion cohort, there were no significant differences in outcomes such as ICU admission and me‐
chanical ventilation for the PSI and CURB-65. All three scores predicted treatment failure with
low to moderate discrimination in the external validation cohort. It must be noted that the ini‐
tial severity of CAP is only one factor predicting treatment failure. Other factors, such as the
causal microorganism and treatment-related factors, are not part of the three prediction tools.
The SCAP score classified a significantly higher proportion of patients as low risk in both co‐
horts than the PSI and CURB-65, with lower rates of all adverse outcomes. Another goal of the
tool is its negative predictive value. If the score is low, ICU admission and others adverse out‐
comes are very unlikely. In addition, patients identified as high risk by the SCAP score had
somewhat higher rates of ICU admissions, need for mechanical ventilation, and severe sepsis
compared with the PSI and CURB-65. Thus, applying the SCAP score would identify CAP pa‐
tients who should receive closer monitoring and more aggressive treatment. Given the some‐
what poorer predictive power of the PSI and CURB-65 in the internal validation cohort, the
sensitivity, specificity, and AUC of the three scores were compared in the external validation
cohort. Although the SCAP score had significantly better sensitivities and specificities than the
PSI and CURB-65, the differences were small and of uncertain clinical relevance.
Saldías et al. [77] assessed the accuracy and discriminatory power of three validated rules
(PSI, CURB-65 and SCAP) for predicting clinically relevant adverse outcomes (ICU admis‐
sion, need for mechanical ventilation and hospital complications rate) in patients hospital‐
ized with community-acquired pneumococcal pneumonia. The rate of all adverse outcomes
and hospital length of stay increased directly with increasing PSI, CURB-65 and SCAP
scores. The three severity scores allowed us to predict the risk of in-hospital complications
and 30-day mortality. The PSI score was more sensitive and the SCAP was more specific to
predict hospital complications and the risk of death. However, the SCAP was more sensitive
and specific in predicting the use of mechanical ventilation. Thus, the severity scores vali‐
dated in the literature allow us to predict the risk of complications and death in adult pa‐
tients hospitalized with pneumococcal pneumonia. Nevertheless, the clinical indexes differ
in their sensitivity, specificity and discriminatory power to predict different adverse events.
3.4. Biomarkers of inflammation for the severity assessment of CAP
The clinical guidelines for the management of adult patients with CAP suggest the use of
severity-based approach for the purpose of guiding therapeutic options, such as the need
for hospital or ICU admission, suitability for ambulatory care, and choice and route of an‐
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timicrobial agents. The use of prognostic scores, like CURB-65 and PSI, is recommended
to support  clinical  judgment [16,17,35].  Despite  their  widespread use in  clinical  routine,
traditional  markers,  such as  severity of  disease assessment by the patient`s  fever,  white
blood cell count and also CRP level are not reliable for the assessment of disease severity
and mortality risk in CAP. The pneumonia severity index (PSI) is a widely accepted and
validated  severity  scoring  system that  assesses  the  risk  of  mortality  for  pneumonia  pa‐
tients in a two step algorithm, combining clinical signs, demographic data and laboratory
values  [81].  However,  its  complexity  is  high,  jeopardizing  its  dissemination  and imple‐
mentation, especially in everyday clinical practice. Therefore, the CURB-65 score has been
proposed as a simpler alternative [79,80].
A number of studies have explored the prognostic value of biomarkers in patients with
CAP. Muller et al. [49] reported a significant relationship between procalcitonin levels and
PSI categories, with PCT being markedly elevated in the highest PSI class. However, it must
be taken into account that many PSI class V patients had low PCT values. Huang et al. [118],
report a multicenter, prospective, observational cohort study in a large population of 1,651
patients admitted to 28 community or teaching emergency departments for CAP to deter‐
mine whether procalcitonin can provide prognostic information beyond the Pneumonia Se‐
verity Index and CURB-65. In this study procalcitonin levels did not add relevant prognostic
information for most pneumonia patients. Used alone, procalcitonin had modest test charac‐
teristics: specificity (35%), sensitivity (92%), positive likelihood ratio (1.41), and negative
likelihood ratio (0.22). However, among higher-risk groups as assessed by the Pneumonia
Severity Index score, low procalcitonin level reliably predicted lower mortality.
The predictive value of procalcitonin was compared to CRP, leukocyte count and CRB-65
score in a large study of the CAPNETZ competence network [119] involving 1,671 patients
with proven CAP, clinical and laboratory variables were determined at admission and pa‐
tients were followed-up for 28 days for outcome. The PCT levels at admission were a better
predictor of CAP severity and outcome than leukocyte count and CRP levels, with a similar
prognostic accuracy as the CRB-65 score. The area under the curve for PCT and CRB-65 was
comparable (0.80, 95%CI 0.75-0.84 versus 0.79, 95%CI 0.74-0.84), but each significantly high‐
er compared with CRP (0.62, 95%CI 0.54-0.68) and leukocyte count (0.61, 95%CI 0.54-0.68).
Another finding from this study, a PCT threshold of ≤ 0.228 ng/mL identified low-risk pa‐
tients within all CRB-65 risk groups.
Another study from the CAPNETZ network explored the role of pro-atrial natriuretic pep‐
tide (MR-proANP), pro-vasopressin (CT-proAVP), PCT and CRP for severity assessment
and outcome prediction in 589 adult patients with CAP [120]. MR-proANP, CT-proAVP and
PCT levels, but not CRP, increased with increasing severity of CAP, classified according to
the CRB-65 score. The area under the curve values for CT-proAVP (0.86, 95%CI 0.83-0.89)
and MR-proANP (0.76, 95%CI 0.72-0.80) were similar to the AUC of CRB-65 (0.73, 95%CI
0.70-0.77). In multivariate Cox proportional hazards regression analyses high levels of MR-
proANP and CT-proAVP were the strongest predictors of mortality. Thus, the authors con‐
cluded that MR-proANP and CT-proAVP are predictors of CAP severity and 28-day
mortality comparable to the clinical CRB-65 score.
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4. Conclusion
In assessing the probability of death in adult patients with community-acquired pneumo‐
nia,  the  clinical  history  and  physical  examination  abnormalities  significantly  influenced
the prognosis [4,6,49,69,75-87]. In medical history, advanced age (over 65-70 years), specif‐
ic comorbidities, symptoms of dyspnea and confusion were associated with increased risk
of death. Among comorbid conditions, the strongest predictors of death were neurologic
disease, cancer, immunosuppression, alcoholism, malnutrition, renal disease, liver disease
and congestive heart failure. In physical examination, altered mental status, hypotension,
tachypnea and hypothermia were associated with increased odds of death. Laboratory ab‐
normalities  significantly  associated  to  bad  prognosis  are  azotemia  (blood  urea  nitrogen
level  above  20  mg/dL),  hypoxemia,  leukopenia  ( ≤  4,000  cells/mm3)  and  leukocytosis  ( ≥
20,000 cells/mm3). Pleural effusion, rapid progression of pulmonary infiltrates and multilo‐
bar  or  bilateral  infiltrates  on chest  radiograph were  also  associated to  increased risk  of
complications and death.
Individual  clinical  and  laboratory  abnormalities  are  associated  with  only  moderate  in‐
creases in the odds of death [6,49,75-87]. Thus, combinations of factors are necessary to ac‐
curately assess short-term risk for death and guide site-of-care decisions. These prognosis
rules  include demographic  factors  (age,  gender  and nursing home residence),  comorbid
conditions  (for  example,  neoplastic  disease,  diabetes,  pulmonary  disease,  and heart  dis‐
ease), symptoms and signs (for example, altered mental status, lack of pleuritic chest pain
or fever, tachypnea, and hypotension), and laboratory and radiographic findings (for ex‐
ample, hypoxemia, azotemia, leukopenia, acidosis, hypoalbuminemia and multilobar infil‐
trates).  The  Pneumonia  Patient  Outcomes  Research  Team  (PORT)  Severity  Index  and
CURB-65  are  well  validated  prognostic  rules  recommended  in  the  clinical  guidelines
[16,17,35] to assess severity of pneumonia patients in the ambulatory care setting. In eval‐
uating clinical findings as a guide to initial  site of treatment,  most studies on prognosis
have focused on mortality as the sole outcome, which is problematic because a high risk
for death may not be the only reason for hospitalization. Increased risk for other serious
adverse events (e.g., ICU admission, mechanical ventilation support, progression to septic
shock), reliability in adhering to therapy, returning for follow-up, and availability of sup‐
portive care at home are also important determinants for hospitalization. Therefore, clini‐
cal judgment should always prevail over the severity index calculation in clinical decision
for site of care and treatment planning.
4.1. Pneumonia severity assessment in the ambulatory setting
Clinicians are advised to implement a simple and practical strategy for assessing the severi‐
ty and risk of complications in patients with community-acquired pneumonia assisted in the
ambulatory care setting (outpatient clinics and emergency departments). It is suggested to
classify patients into three risk categories:
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a. Low-risk patients (short-term mortality less than 1-2%) susceptible to ambulatory treat‐
ment or brief hospitalization.
b. High-risk patients (short-term mortality around 20-30%) that must be managed in the
hospital and probably in specialized units (Intermediate Care Unit or ICU) with severe
pneumonia criteria.
c. Intermediate-risk patients with advanced age, comorbidities or independent risk factors
of death, but they cannot be classified into a specific category.
Clinical judgment is essential to decide the setting of care and treatment of patients with
community-acquired pneumonia, especially those located in the intermediate risk catego‐
ry. In general, patients younger than 65 years without preexisting diseases, abnormal vital
signs or altered mental status at admission, could be managed as outpatients considering
its low risk of death and complications. Elderly patients (aged above 65 years) with specif‐
ic  comorbidities  and  two  or  more  risk  factors  from  the  British  Thoracic  Society  rule
(CURB-65), it is recommended to handle them in the hospital with severe pneumonia cri‐
teria.
In primary health care services, we recommend to assess the severity of adult patients with
community acquired pneumonia considering only clinical variables available in primary
care services:
• Age over 65 years.
• Comorbidity: coronary heart disease, congestive heart failure, chronic pulmonary disease
(COPD, bronchiectasis), diabetes mellitus, cerebrovascular disease with motor dysfunc‐
tion or dementia, chronic renal failure, chronic liver disease, alcoholism, malignancies,
malnutrition.
• Altered mental status: drowsiness, stupor, coma or mental confusion.
• Tachycardia or heart rate ≥ 120 beats/min.
• Low blood pressure or hypotension (BP < 90/60 mmHg).
• Tachypnea or respiratory rate ≥ 20 breaths/min.
• Chest X-ray: bilateral or multilobar pulmonary infiltrates, cavitation or pleural effusion.
• Pulse oximetry: SpO2 saturation less than 90% on room air.
• Presence of decompensated comorbidity (e.g., COPD exacerbation, congestive heart fail‐
ure, myocardial infarction, hyperglycemia, arrhythmias).
In general terms, in young adults without risk factors it is recommended outpatient man‐
agement, in presence of one risk factor it is recommended ambulatory or short-term hospital
care depending on previous experience and clinical judgment, in presence of two or more
risk factors it is recommended to refer the patient to the hospital (Figure 1).
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Figure 1. Severity assessment in adult patients with community-acquired pneumonia attended in primary
health care services (outpatient clinics and emergency departments).
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Nevertheless, after evaluating the severity of the case, when the clinician needs to decide the
site of care (outpatient or hospital admission), it is important to consider the clinical and so‐
cial variables involved in each particular case. We should especially avoid that high-risk pa‐
tients receive outpatient treatment, but it is also important to minimize the number of low-
risk patients that are unnecessarily admitted to hospital. Different studies have allowed
developing a list of risk factors that determine the need for hospital admission and aid the
clinicians in estimating the severity of CAP patients. Clinical judgment and experience of
the physician must predominate over predictive models, which are not infallible, and
should always consider the aspirations and concerns of patients in making decisions about
the site of care and treatment prescribed.
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